Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
WO2007075215A2
Identification of novel protein targets on the surface of stressed cells
EP1943276A2
Crystal structure of human urokinase plasminogen activator amino terminal fragment bound to its receptor
WO2007142626A1
Methods and compositions for increasing bioavailability of thiomolybdate and thiotungstate compounds
EP1904078A1
Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds
WO2006089298A2
Pyrimidine-fused diazepine derivatives and indole-fused pteridines
KR20070100832A
Compositions containing the anti-angiogenic phscn peptide
KR20070100411A
Acid addition salts of ac-phscn-nh2
KR20070047246A
Ligands binding the complex of urokinase-type plasminogen activator(upa) and its receptor(upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
EP1721010A2
Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
WO2005082382A1
Formulations of thiomolybdate or thiotungstate compounds and uses thereof
ZA200500921B
Thiomolybdate analogues and uses thereof
AU2004290585A1
Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US2006160805A1
Thiotungstate analogues and uses thereof
BR0316550A
Compound, pharmaceutical composition, and methods for treating or preventing cancer in a patient, and for detecting cancer in a patient
ZA200504222B
Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
WO2004024877A2
Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent
AU2003218194A1
Cell surface tropomyosin as a target of angiogenesis inhibition
WO02064621A2
Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
